In Duke University v. Biomarin Pharmaceutical,  the patentee-licensor-appellant Duke challenges an Inter Partes Review Patent Office invalidity ruling.  As summarized by Duke in its argument at the Federal Circuit, “[t]he ***patent *** claims the first method for successfully treating a fatal disorder known as Pompe disease *** using hGAA derived from CHO cell cultures.”

Oral argument will be at the Federal Circuit on February 10, 2017.

Details of the case are found in the attached Top Patent Cases.

TopPatentCasesDec26

Regards,
Hal